- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT06877221
L'efficacia e la sicurezza del catetere di ablazione del nervo ad ultrasuoni utilizzato in combinazione con il dispositivo di ablazione del nervo ad ultrasuoni per il trattamento dell'ipertensione refrattaria o dell'ipertensione nei pazienti con intolleranza ai farmaci (ModulationHTN2)
Uno studio clinico prospettico, multicentrico, randomizzato e controllato per valutare l'efficacia e la sicurezza di un catetere di denervazione renale ad ultrasuoni in combinazione con un dispositivo di denervazione renale ad ultrasuoni per il trattamento dell'ipertensione refrattaria o dell'ipertensione intollerante
Prospective, multicenter, randomized, controlled, blinded, and superiority - designed; The target population undergoes a screening treatment with prescribed medications for at least 4 weeks. Eligible subjects are randomly assigned to the experimental group and the control group at a ratio of 2:1. The experimental group is treated with the ultrasound nerve ablation catheter and the ultrasound nerve ablation device of Shenzhen Maiwei Medical Technology Co., Ltd., while the control group only undergoes renal arteriography (regarded as a sham operation). Within 6 months after the operation, both groups continue to receive antihypertensive drug treatment with the dosage and types specified during the screening period. The subjects are kept blinded during the study. The relative change values of the average 24 - hour ambulatory systolic blood pressure from the baseline at 6 months after the operation are compared between the two groups.
Panoramica dello studio
Stato
Intervento / Trattamento
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
-
Guangzhou, Cina
- Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Age between 18 and 70 years old (calculated based on the date of starting standardized medication).
- After treatment with at least two types of antihypertensive drugs for 4 weeks or more, the clinic systolic blood pressure is ≥140 mmHg and ≤180 mmHg, and the average 24 - hour ambulatory systolic blood pressure is ≥130 mmHg (or the daytime ambulatory systolic blood pressure is ≥135 mmHg).
- Resting heart rate ≥70 beats per minute without taking beta - blockers (this criterion does not apply to patients taking beta - blockers).
- The subject agrees to participate in this clinical trial, complies with the follow - up required by the trial protocol, and has voluntarily signed the informed consent form
Exclusion Criteria:
- CTA, MRA, or DSA examination shows that the shape and structure of the unilateral or bilateral renal arteries are not suitable for ablation surgery (renal artery stenosis exceeding 50%, renal artery aneurysm, fibromuscular dysplasia of the renal artery, or the diameter of the main renal artery is less than 3 mm).
- Having only one kidney or having received a kidney transplant.
- Having a history of renal artery interventional treatment or renal denervation surgery.
- Suffering from any condition that may affect the accuracy of blood pressure measurement, such as the upper arm diameter being too large relative to the cuff.
- Secondary hypertension (excluding apnea syndrome).
- Glomerular filtration rate (eGFR) < 45 mL/min/1.73m² (MDRD formula).
- Having a history of hospitalization due to hypertensive crisis within one year before randomization for enrollment.
- Suffering from type 1 diabetes.
- Suffering from primary pulmonary hypertension.
- Being allergic to contrast agents.
- Severe cardiac valve stenosis.
- Cardiac insufficiency (NYHA class III - IV).
- Hyperthyroidism or hypothyroidism.
- Requiring mechanical ventilation for assisted breathing (except for nocturnal respiratory support for treating sleep apnea).
- Acute or severe systemic infection.
- Having an implantable cardioverter - defibrillator (ICD) or pacemaker.
- Having obvious symptoms of active peptic ulcer (such as abdominal pain, nausea, vomiting, regurgitation, etc.).
- Having obvious bleeding tendency and hematological diseases.
- Having a history of surgery or trauma requiring hospitalization within 30 days before randomization for enrollment.
- Having a cardiovascular event (stable or unstable angina, myocardial infarction) or cerebrovascular event (stroke, cerebrovascular accident, transient ischemic attack) within 6 months before randomization for enrollment.
- Pregnant, lactating women, or women planning to become pregnant during the study period.
- Currently participating in other clinical trials of drugs or medical devices.
- Other reasons that the investigator deems inappropriate for participation in this study
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Quadruplicare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: denervazione renale ad ultrasuoni
|
Treat with an ultrasound nerve ablation catheter and an ultrasound nerve ablation device |
|
Comparatore fittizio: Arteriografia renale
|
Treat with an ultrasound nerve ablation catheter and an ultrasound nerve ablation device |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
The average change value of 24 - hour ambulatory systolic blood pressure (ASBP) relative to the baseline
Lasso di tempo: Six months after surgery
|
The average change value of 24 - hour ambulatory systolic blood pressure (ASBP) relative to the baseline at 6 months after surgery |
Six months after surgery
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
The change values of clinic systolic blood pressure and diastolic blood pressure relative to the baseline
Lasso di tempo: 3 months and 6 months after surgery
|
The changes in clinic systolic and diastolic blood pressures relative to the baseline at 3 months and 6 months after surgery |
3 months and 6 months after surgery
|
|
The attainment rate of clinic diastolic blood pressure
Lasso di tempo: 3 months and 6 months after surgery
|
The attainment rate of clinic systolic blood pressure (90 mmHg ≤ SBP < 140 mmHg) at 3 months and 6 months after surgery The attainment rate of clinic systolic blood pressure (90 mmHg ≤ SBP < 140 mmHg) at 3 months and 6 months after surgery The attainment rate of clinic systolic blood pressure (90 mmHg ≤ SBP < 140 mmHg) at 3 months and 6 months after surgery |
3 months and 6 months after surgery
|
|
The average change value of 24 - hour ambulatory diastolic blood pressure relative to the baseline
Lasso di tempo: 3 months and 6 months after surgery
|
The average change values of 24 - hour ambulatory diastolic blood pressure relative to the baseline at 3 months and 6 months after surgery |
3 months and 6 months after surgery
|
|
The average change value of 24 - hour ambulatory systolic blood pressure relative to the baseline
Lasso di tempo: Three months after surgery
|
The average change value of 24 - hour ambulatory systolic blood pressure relative to the baseline at 3 months after surgery |
Three months after surgery
|
|
The proportion of patients with a reduction in clinic systolic blood pressure of ≥5 mmHg, 10 mmHg, 15 mmHg, and 20 mmHg
Lasso di tempo: 3 months and 6 months after surgery
|
The proportion of patients with a reduction in clinic systolic blood pressure of ≥ 5 mmHg, 10 mmHg, 15 mmHg, and 20 mmHg at 3 months and 6 months after surgery |
3 months and 6 months after surgery
|
|
Changes in the drug composite index of the types and dosages of antihypertensive medications
Lasso di tempo: Six months after surgery
|
Changes in the drug composite index of the types and dosages of antihypertensive drugs 6 months after surgery |
Six months after surgery
|
Collaboratori e investigatori
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- MW-URDN202501
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .